Tag: prophylaxis

Posted on

Efficacy of Vancomycin Powder Prophylaxis in 987 Cranial Surgeries for Nonmalignant Pathology

Neurosurgery 98:1076–1084, 2026

This study evaluates whether prophylactic subgaleal vancomycin powder reduces surgical site infections (SSIs) after 987 craniotomies for nonmalignant pathology. In a retrospective cohort (682 with vancomycin, 305 without), overall SSI incidence was very low and did not differ significantly between groups, with six infections recorded and diverse cultured pathogens.

The authors contrast prior studies biased toward malignant, high-risk populations, discuss potential harms of indiscriminate vancomycin use (resistance, wound complications), and recommend a more selective, evidence-based application while calling for larger multicenter research to define high-risk subgroups and dosing effects.

Objective Assess whether prophylactic subgaleal vancomycin powder reduces surgical site infections (SSI) in nonmalignant cranial surgeries.

Design Retrospective chart review of 987 nonmalignant cranial surgeries (July 2021–June 2024), comparing vancomycin powder (n=682) vs no vancomycin powder (n=305).

Intervention Vancomycin cohort received 1 g powder applied over the bone flap before galeal closure; all patients received standard IV cefazolin, chlorhexidine prep, and postoperative incisional bacitracin.

Primary outcome SSI incidence was not significantly different: 0.3% without vancomycin vs 0.7% with vancomycin (P = .578), with 6 total infections.

SSI distribution Infections occurred mainly with atypical meningiomas (3/6) and schwannomas (2/6), plus 1 amoebic abscess case.

Pathogens 7 pathogens were cultured from 6 SSI cases; Cutibacterium acnes was most common (3/6), and Klebsiella aerogenes occurred in 2 vancomycin cases (vancomycin-resistant).

Interpretation Routine prophylactic vancomycin powder in nonmalignant cranial surgery may be unnecessary given the very low SSI rate and lack of demonstrated benefit.

Caveats Retrospective design with potential selection bias and only 6 SSI events; larger/multicenter studies are needed to identify any high-risk subgroups who might benefit.

Posted on

Anticonvulsant prophylaxis for brain tumor surgery

Seizures frequency

J Neurosurg 121:1139–1147, 2014

Patients who undergo craniotomy for brain tumor resection are prone to experiencing seizures, which can have debilitating medical, neurological, and psychosocial effects.

A controversial issue in neurosurgery is the common practice of administering perioperative anticonvulsant prophylaxis to these patients despite a paucity of supporting data in the literature. The foreseeable benefits of this strategy must be balanced against potential adverse effects and interactions with critical medications such as chemotherapeutic agents and corticosteroids. Multiple disparate metaanalyses have been published on this topic but have not been applied into clinical practice, and, instead, personal preference frequently determines practice patterns in this area of management.

Therefore, to select the current best available evidence to guide clinical decision making, the literature was evaluated to identify meta-analyses that investigated the efficacy and/or safety of anticonvulsant prophylaxis in this patient population. Six meta-analyses published between 1996 and 2011 were included in the present study.

The Quality of Reporting of Meta-analyses and Oxman-Guyatt methodological quality assessment tools were used to score these meta-analyses, and the Jadad decision algorithm was applied to determine the highest-quality meta-analysis. According to this analysis, 2 metaanalyses were deemed to be the current best available evidence, both of which conclude that prophylactic treatment does not improve seizure control in these patients.

Therefore, this management strategy should not be routinely used.

Proudly powered by WordPress